This website contains unedited verbatim presentations made by meeting participants and is not an official report of the National Academies. Opinions and statements included in this material are solely those of the individual authors. They have not been verified as accurate, nor do they necessarily represent the views of other participants, the committee, or the National Academies. November 16, 2016 Making the Living World Engineerable: Science, Practice, and Policy Washington, DC View Agenda
Presentations *Scott Fahrenkrug - see video at: http://kstp.com/news/gene-editing-supply-medical-research-recombinetics/4315545/ *Kevin Esvelt, "Living Technologies for Ecological Problems" *Rob Carlson, "Ubiquitous Biological Manufacturing" *Lionel Clarke, "Policy Levers and Strategies: Making the Living World Engineerable - The UK Approach" *Jane Calvert, "A Synthetic Biology Roadmap for the UK" *Laurie Zoloth, "Ethics: Recent Histories and Narratives" *Jason Delborne, "Engagement as Governance" View Report of Proceedings View Roster of Workshop Planning Committee October 28-29, 2014 Creating an Environment to Support Investment and Innovation in Synthetic Biology London, England Agenda Read UK Synthetic Biology Leadership Council Summary Report of Meeting September 18-19, 2014 3rd Meeting Washington, DC Agenda
Presentations *Sarah R. Carter, "Synthetic Biology and the U.S. Biotechnology Regulatory System: Challenges and Options" *Thomas M. Connelly, "Synthetic Biology and Advanced Manufacturing - A Chemical Industry Perspective" *Floyd Romesberg, "Artificial DNA in Living Cells" *Frank F. Weichold, "FDA Oversight of Synthetic Biology" March 13, 2014 2nd Meeting: Understanding Risk Frameworks for Emerging Technologies Palo Alto, CA Agenda Video Presentations *Lynne P. Cooper, "Pre-Quantitative Risk: The Social Construction of Risk in Project Teams" "Adam Finkel, "Channeling Synthetic Biology Through 'Solution-Focused Risk Assessment'" *Stephen Hilgartner, "The Politics of Risk" *Sheila Jasanoff, "International Approaches to Risk (Understanding Risk Frameworks for Emerging Technologies)" *Jennifer Kuzma, "Beyond Old Debates: New Systems Risk Analysis (NESRA) in an Action Oriented Approach" *Andrew D. Maynard, "Innovative Approaches to Emergent Risks" *Jonathan Wiener, "Learning from Research about Risk Regulation" October 20-21, 2013 1st Meeting Washington, DC Agenda Presentations *Linda Chrisey, "Office of Naval Research Synthetic Biology" *Denver Dale, "Specialized Capital Formation and Deployment to Support Synthetic Biology" *Philip Dormitzer, "Synthetic Vaccinology at Novartis" *Antony Evans, "Glowing Plant" *Theresa Good, "NSF Investments in Synthetic Biology" *Alicia Jackson, "Engineering Biology" *Megan Palmer, "Enabling Next Generation Synthetic Biology Leadership" *Alan Pearson, The Role of USDA-APHIS in the Regulation of Biotechnology in the United States" *Pablo Rabinowicz, "DOE Office of Biological and Environmental Research (BER) Genomic Science Program: Biosystems Design" *Marc Salit, "National Institute of Standards and Technology" *Mark Segal, "EPA Oversight of Synthetic Biology" *William So, "Synthetic Biology and National Security" August 16, 2013 The Evolving Nature of Synthetic Biology: A Panel Discussion on Key Science, Policy, and Societal Challenges Facing the International Community Washington, DC Agenda Video Presentations *Drew Endy, "What and Why Is Synthetic Biology" *Richard Johnson, "Synthetic Biology: Ten Policy Reasons It Matters to U.S. Foreign Policy" *Eleonore Pauwels, "Lost in Translation: Sharing Knowledge on the Technological Frontier" August 1, 2013 Virtual Meeting This meeting was closed in its entirety. July 15-16, 2013 Ownership and Sharing: Setting the Patent Framework for Innovation in Synthetic Biology, A Workshop London, England Meeting Summary Agenda Presentations *Robert Wells, Synthetic Biology and the Bioeconomy *Rob Carlson, The Bioeconomy, IP, and Synthetic Biology *Rochelle C. Dreyfuss, The Patent Landscape: Recent Decisions from the U.S. Supreme Court *Linda Kahl, How Synthetic Biology Challenges Current Patenting/Ownership Frameworks *Joanne Kamens, Addgene: A Unique Non-Profit Biotech *Drew Endy, From Genetic Engineering to Synthetic Biology *Lionel Clarke, Synthetic Biology Ownership and Innovation: Industry and Other Perspectives *Stephen Laderman, Case Study: Agilent Technologies - Freedom to Operate Summaries of the proceedings of forum activities may be published as NRC reports. Co-chairs: Vicki L. Chandler (NAS) Dean of Natural Sciences Minerva Schools at Keck Graduate Institute Richard M. Murray (NAE) Thomas E. and Doris Everhart Professor of Control and Dynamical Systems and Bioengineering California Institute of Technology Members: Steven A. Benner Director The Foundation for Applied Molecular Evolution (Ffame) Jef D. Boeke (NAS) Director Institute for Systems Genetics New York University Langone School of Medicine
Rob Carlson Principal Biodesic LLC R. Alta Charo (NAM) Warren P. Knowles Professor of Law and Bioethics Department of Medical History and Bioethics School of Medicine and Public Health University of Wisconsin-Madison Laura K. Donohue Professor of Law Georgetown University Law Center Drew Endy Assistant Professor, Bioengineering Stanford University President The BioBricks Foundation Richard A. Johnson Chief Executive Officer GlobalHelix LLC Claire Marris Senior Research Fellow Department of Social Science, Health and Medicine Kings College London Darlene J.S. Solomon Senior Vice President and Chief Technology Officer Agilent Technologies
Ex Officio Members:
Linda Chrisey Program Officer Office of Naval Research Genya Dana Office of the Science and Technology Adviser to the Secretary U.S. Department of State Barbara Gerratana Program Director National Institute of General Medical Sciences Marc Salit Group Leader National Institute of Standards and Technology Jessica M. Tucker Program Director National Institute of Biomedical Imaging and Bioengineering Edward You Supervisory Special Agent Federal Bureau of Investigation
This project was initially sponsored by the Alfred P. Sloan Foundation and Agilent Technologies. It was subsequently been sponsored by the National Institute of Biomedical Imaging and Bioengineering, the U.S. Department of Homeland Security, and the Federal Bureau of Investigation.
|